The Latest Information about i-FACTOR and Cerapedics

Cerapedics announces closing of venture debt loan from GE Capital

Cerapedics today announced closing of a $9 million venture debt financing from GE Capital, Healthcare Financial Services.

Find out more

Cerapedics announces positive results from IDE clinical trial

Results provide significant support to advance i-FACTOR™ Peptide Enhanced Bone Graft for FDA regulatory review.

Find out more

Cerapedics to present preliminary outcomes data From i-FACTOR Bone Graft Study at Canaccord Genuity Musculoskeletal Conference

Cerapedics today that preliminary outcomes data from the company's FDA Investigational Device Exemption (IDE) clinical trial for i-FACTOR Peptide Enhanced Bone Graft will be presented at the Canaccord Genuity Muscul…

Find out more